Table 1

P P No Anemia,
No Anemia, P Value
P Value Anemia, Overall,
Overall,
ValueValue n= 1342 (62.80%) Anemia, n=2138
n= 1342 (62.80%) n=n=
796 (37.20%)
796 (37.20%) n=2138

PCIPCI CABG (n=524)

CABG (n=524) PCI
PCI CABG
CABG
(n=818)
(n=818) (n=404)
(n=404) (n=392)
(n=392)
Hospital
Baseline presentation
characteristics
0.023
< 0.001 32 (3.90%)
65.9 ± 9.6 9 (1.70%)
60.7 ± 9.7 0.105
0.007 1964.4
(4.70%)
±11.1 10 62.6±9.9
(2.60%) 70 (3.3%)
63.7 ± 10.2 Cardiac arrest,
Age (years), n (%)
mean ± SD

0.055 29.2 ± 5.1 28.6 ± 5.3 0.002 29.4 ± 5.0 28.3 ± 5.2 28.8 (5.10) Type
Bodyof cardiac
mass arrest,
index (kg/mn2(%)
), mean ± SD
0.106
< 0.001 20 551
(2.44%)
(67.40%) 6441
(1.15%)
(84.20%) >0.99
0.288 7 (1.73%)
343 (84.90%) 6 (1.53%)
343 (87.50%) 39 (1.82%)
1678 (78.5%) Ventricular fibrillation
Gender (male), n (%)
0.1830.872 12 332
(1.47%)
(40.60%) 3215
(0.57%)
(41.00%) 0.074
0.359 12 (2.97%)
147 (36.40%) 4 (1.02%)
155 (39.50%) 31 (1.44%)
849 (39.7%) Pulseless
Smoker, nelectrical
(%) activity/Asystole

0.001 524 (64.10%) 380 (72.50%) 0.329 280 (69.30%) 284 (72.40%) 1468 (68.7%) Type of arrhythmia,
Diabetes mellitus, n n(%)
(%)

0.4640.847 22(2.69%)
566 (70.00%) 10364
(1.91%)
(69.50%) 0.020
0.188 13 (3.22%)
293 (73.60%) 3 (0.77%)
272 (69.40%) 48 (2.24%)
1495 (70.4%) Atrial arrhythmia
Hypertension, n (%)
0.2240.132 33(70.20%)
526 (65.10%) 14362
(29.80%)
(69.10%) 0.022
0.363 24 (5.94%)
295 (74.30%) 10 (29.41%)
280 (71.40%) 81 (3.79%)
1463 (69.0%) Ventricular arrhythmia
Dyslipidemia, n (%)
0.021
< 0.001 12(1.47%)
139 (17.00%) 1 (0.19%)
31 (5.90%) 0.124
0.016 4 (0.99%)
57 (14.10%) 034
(0.00%)
(8.70%) 17 (7.95%)
261 (12.2%) Brady arrhythmia
Congestive heart failure, n (%)
0.001 57 (7.00%) 15 (2.90%) 0.001 44 (10.90%) 1 (4.60%) 134 (6.3%) Cardiogenic shock, n (%)
< 0.001 136 (16.60%) 34 (6.50%) 0.023 48 (11.90%) 28 (7.10%) 246 (11.5%) Peripheral arterial disease, n (%)
0.974 146 (17.90%) 94 (17.90%) 0.166 68 (16.80%) 81 (20.70%) 389 (18.2%) ST-elevation myocardial infarction
< 0.001 371 (45.40%) 185 (35.30%) < 0.001 198 (49.00%) 141 (36.00%) 895 (41.9%) Coronary artery disease, n (%)
0.471 439 (53.70%) 271 (51.70%) 0.907 189 (46.80%) 185 (47.20%) 1084 (50.7%) Non ST-elevation acute coronary syndrome
< 0.001 131 (16.00%) 24 (4.60%) < 0.001 48 (11.90%) 19 (4.80%) 222 (10.4%) Cerebral vascular accident, n (%)
0.06 94 (11.50%) 88 (16.80%) 0.628 46 (11.40%) 49 (12.50%) 277 (13.0%) Stable coronary artery disease
< 0.001 217 (26.50%) 61 (11.60%) 0.001 99 (24.50%) 60 (15.30%) 437 (20.4%) Chronic kidney disease, n (%)
0.1 138 (16.90%) 71 (13.50%) 0.07 101 (25.00%) 77 (19.60%) 387 (18.1%) Silent ischemia/Others
< 0.001 123 (15.00%) 15 (2.90%) 0.012 31 (7.70%) 14 (3.60%) 183 (8.6%) Atrial fibrillation, n (%)
0.001 44.3 ± 11.1 47.9 ± 11.8 < 0.001 41.0 ± 11.5 45.9 ± 11.3 44.8 ± 11.6 Left ventricular ejection fraction (%),
< 0.001 192 (23.50%) 66 (12.60%) < 0.001 97 (24.00%) 44 (11.20%) 399 (18.7%) Family(SD)
mean history of CAD, n (%)
0.478 78.4 ± 24.5 77.5 ± 21.4 0.003 70.5 ± 27.5 75.8 ± 22.3 76.2 ± 24.2 Creatinine clearance (ml/min), mean (SD)
< 0.001 270 (33.00%) 106 (20.20%) < 0.001 148 (36.60%) 89 (22.70%) 613 (28.7%) Previous myocardial infarction, n (%)
(pre-revascularization)
< 0.001 4.5 ± 4.9 3.2 ± 3.7 0.012 4.3 ± 6.0 3.3 ± 4.6 3.9 (4.9) EuroSCORE score, mean (SD)

Table 2
Table 3

P No Anemia, No Anemia, P
P Value P Value Anemia, Overall, Overall,
Value n= 1342 (62.80%) Value Anemia, n=2138
n= 1342 (62.80%) n=2138
n= 796 (37.20%) n= 796 (37.20%)
PCI CABG (n=524) PCI CABG
(n=818) PCI CABG (n=404) (n=392)
PCI CABG
(n=818) (n=524) (n=404) (n=392) Angiographic characteristics
Discharge medications
Medina classification, n (%)
0.153 0.065 2010 ASA,
0.8 292 (35.70%) 784
190(99.70%)
(36.30%) 485 (99.20%)
0.6 138 (34.20%) 384
140(99.20%)
(35.70%) 357
760(97.50%)
(35.5%) 1,1,1
(99.10%) n (%)
0.0001 < 0.001
204 (24.90%) 51 (9.70%) 0.0001 106 < 0.001
(26.20%) 41 (10.50%) 162 (7.6%) 1,0,1 1833 P2Y12 inhibitors,
782 (99.50%) 389 (79.60%) 387 (100.00%) 275 (75.10%)
0.0001 34 (4.20%) 65 (12.40%) 0.0001 14 (3.50%) 49 (12.50%) 393 (18.4%) (90.40%)
0,1,1 n (%)
< 0.001 0.047 1914 Beta blocker, Table 4
0.2 157 (19.20%) 76287(96.90%)
(16.60%) 0.9
447 (91.40%) 75 (18.60%) 36974(95.30%)
(18.90%) 402(91.80%)
336 (18.8%) 1,1,0
(94.40%) n (%)
0.9 81 (9.90%)
< 0.001 53 (10.10%) 0.8 35 <(8.70%)
0.001 33 (8.40%) 202 (9.4%) 1,0,0 1934 Statin,
0.0001 34 (4.20%) 77764(98.90%)
(12.20%) 4430.011
(90.60%) 22 (5.40%) 38440(99.20%)
(10.20%) 330 (90.20%)
160 (7.5%) 0,1,0
(95.40%) n (%)
0.8 < 0.001
9 (1.10%) 5 (1.00%) 0.2 < 0.001
2 (0.50%) 5 (1.30%) 21 (1.0%) 0,0,1 1516 ACE inhibitors or ARB,
698 (88.80%) 277 (56.60%) 351 (90.70%) 190 (51.90%)
(74.80%)
Lesion n (%)
characteristics
Medications during follow-
0.0001 387 (47.30%) 339 (64.70%) 0.0001 192 (47.50%) 284 (72.40%) 1202 (56.2%) upn (%)
Multivessel disease,
0.801 0.201 1713 ASA,
0.0001 173 (21.10%) 69320(97.10%)
(3.80%) 3920.0001
(96.80%) 78 (19.30%) 34016 (4.10%)
(98.00%) 287(96.30%)
288 (13.4%) LAD, n (%)
(97.10%) n (%)
0.004 23 (2.80%)
< 0.001 3516
(0.60%) 0.16 7 (1.70%)
< 0.001 2 (0.50%) 35 (1.6%) LCX,1129
n (%) P2Y12 inhibitors,
0.12 117 (14.30%) 91 (17.40%) 2020.03
(49.90%) 71 (17.60%) 26248(75.50%)
(12.20%) 149
327(49.80%)
(15.3%) LAD and LCX, n (%)
(72.30%) (64.00%) n (%)
0.7 0.145
4 (0.50%) 0.386 RCA,1674 Beta blocker,
6812(95.40%)
(0.40%) 0.4
378 (93.30%) 3 (0.70%) 1 (0.30%)
328 (94.50%) 10 (0.5%)
287 (96.00%) n (%)
0.01 45 (5.50%) 47 (9.00%) 0.15 19 (4.70%) 28 (7.10%) 139 (6.5%) (94.80%)
RCA + (LAD or LCX),n (%) n (%)
0.219 0.009 1727 Statin,
0.002 69 (8.40%) 70522(98.70%)
(4.20%) 3960.002
(97.80%) 34 (8.40%) 34213(98.60%)
(3.30%) 284 (95.00%)
138 (6.5%) Isolated left main disease, n (%)
(97.80%) n (%)
< 0.001 < 0.001 SYNTAX 1332 score ACE inhibitors or ARB,
61966(86.70%)
(12.70%) 2420.0001
(59.80%) 112 (27.80%) 30560(87.90%) 166
0.0001 192 (23.50%) (15.40%) 430(55.50%)
(20.2%) Low(75.50%)
(≤ 22), n (%)n (%)
0.002 488 (59.70%) 263 (50.70%) 0.08 193 (47.90%) 163 (41.90%) 1107 (52.0%) Intermediate (23-32), n (%)
0.0001 138 (16.90%) 190 (36.60%) 0.0001 98 (24.30%) 166 (42.70%) 592 (27.8%) High (≥ 33), n (%)
0.001 27.5 ± 7.3 30.8 ± 8.9 0.001 27.9 ± 8.7 31.0 ± 8.8 29.0 (8.4) SYNTAX score, mean (SD)
Lesion location

0.0001 145 (17.70%) 178 (34.00%) 0.003 90 (22.30%) 123 (31.40%) 536 (25.1%) Ostial/shaft only, n (%)
0.0001 673 (82.30%) 346 (66.00%) 0.003 314 (77.70%) 269 (68.60%) 1602 (74.9%) Distal bifurcation, n (%)
Procedure
0.047 55 (6.70%) 51 (9.70%) 0.301 43 (10.60%) 51 (13.00%) 200 (9.4%) Intra-aortic ballon pump, n (%)
0.413 6 (0.70%) 2 (0.40%) 0.015 6 (1.50%) 0 (0.00%) Impella, n (%)
Table 5

P No Anemia, P Value Anemia, Overall,

Value n= 1342 (62.80%) n= 796 (37.20%) n=2138

PCI CABG PCI CABG

(n=818) (n=524) (n=404) (n=392)
In-hospital events

0.35 25 (3.10%) 21 (4.00%) 0.23 14 (3.50%) 21 (5.3%) 81 (3.8%) Cardiac death, n (%)

0.23 5 (0.60%) 7 (1.3%) 0.02 2 (0.50%) 10 (2.5%) 24 (1.1%) Non-cardiac death, n (%)

< 0.001 12 (1.50%) 30 (5.70%) < 0.001 6 (1.50%) 25 (6.40%) 73 (3.4%) Myocardial infarction, n (%)

0.84 4 (0.50%) 3 (0.60%) 0.30 1 (0.20%) 3 (0.80%) 11 (0.5%) Target lesion revascularization, n (%)

0.48 5 (0.60%) 5 (1.00%) 0.63 2 (0.50%) 3 (0.80%) 15 (0.7%) Target vessel revascularization, n (%)

0.19 11 (1.30%) 12 (2.30%) 0.053 8 (2.00%) 17 (4.30%) 48 (2.2%) Cerebrovascular events, n (%)

0.10 34 (4.20%) 34 (6.48%) 0.006 20 (5.00%) 37 (9.44%) 125 (5.8%) MACCE, n (%)

0.87 31 (3.80%) 19 (3.60%) 0.55 18 (4.50%) 21 (5.40%) 89 (4.2%) Congestive heart failure, n (%)

0.41 104 (12.70%) 75 (14.30%) 0.13 60 (14.90%) 74 (18.90%) 313 (14.6%) Major bleeding, n (%)

0.008 49 (6.00%) 52 (9.90%) 0.004 18 (4.50%) 38 (9.70%) 157 (7.3%) Minor bleeding, n (%)

0.14 30 (3.70%) 28 (5.34%) 0.02 16 (4.00%) 31 (7.90%) 105 (4.9%) Total mortality, n (%)

< 0.001 3 (5) 11 (7) < 0.001 3 (6) 12 (8) 7 (9) Duration of hospital stay, median (IQR)
(Days)
Table 6

Pre-discharge hemoglobin level Overall, Very low Hb P Low Hb P Normal Hb P

n=2033 (<80 g/L for men & Value ( ≥80 & ≤119 g/L for women Value (≥130 g/L for men & ≥120 g/L Value
women) & ≤129 g/L for men) for women)
n=50 (2.5%) n=1018 (50%) n=965 (47.5%)
CABG PCI CABG PCI CABG PCI
(n=34) (n=16) (n=585) (n=433) (n=238) (n=727)
Follow-up events

Cardiac death, n (%) 14 (0.7%) 0 (0.0%) 1 (6.3%) 0.14 6 (1.03%) 0 (0.0%) 0.049 0 (0.0%) 7 (0.95%) 0.10

Non-cardiac death, n (%) 25 (1.2%) 2 (5.9%) 1 (6.3%) 0.9 10 (1.7%) 3 (0.7%) 0. 1 (0.4%) 8 (1.1%) 0.3

Myocardial infarction, n (%) 50 (2.5%) 4 (11.8%) 1 (6.3%) 0.9 13 (2.2%) 8 (1.8%) 0.6 9 (3.8%) 15 (2.1%) 0.14

Target lesion revascularization, 55 (2.7%) 6 (17.6%) 1 (6.3%) 0.28 9 (1.5%) 15 (3.5%) 0.04 3 (1.3%) 21 (2.9%) 0.17
n (%)
Target vessel revascularization, n (%) 60 (3%) 6 (17.6%) 1 (6.3%) 0.28 13 (2.2%) 15 (3.5%) 0.2 8 (3.4%) 17 (2.3%) 0.35

Cerebrovascular events, n (%) 31 (1.5%) 3 (8.8%) 0 (0.0%) 0.2 11 (1.9%) 6 (1.4%) 0.5 2 (0.8%) 9 (1.2%) 0.6

MACCE, n (%) 108 (5.3%) 12 (35.3%) 2 (12.5%) 0.1 25 (4.3%) 24 (5.5%) 0.35 8 (3.4%) 37 (5.1%) 0.10

Congestive heart failure, n (%) 415 (20.4%) 6 (17.6%) 6 (37.5%) 0.12 68 (11.6%) 145 (33.5%) 0.0001 46 (19.3%) 144 (19.8%) 0.8

Major bleeding, n (%) 8 (0.4%) 0 (0.0%) 0 (0.0%) 1 2 (0.3%) 1 (0.2%) 0.7 1 (0.4%) 4 (0.6%) 0.7

Minor bleeding, n (%) 32 (1.6%) 1 (2.9%) 0 (0.0%) 0.49 9 (1.5%) 5 (1.2%) 0.6 6 (2.5%) 11 (1.5%) 0.3

Total mortality, n (%) 39 (1.9%) 2 (5.9%) 2 (12.5%) 0.5 16 (2.7%) 3 (0.7%) 0.04 1 (0.4%) 15 (2.0%) 0.11

Median follow up time (IQR) 20 (27) 23 (24) 19 (33) 0.99 15 (26) 22 (26) 0.01 19 (31) 20 (25) 0.85
(months)